The FDA considers how safe and effective a new drug is before approving it. But for addictive opioid painkillers, which have triggered a massive public health crisis, should the agency also weigh the potential for the medication to be abused?
That’s... Read more »
For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those abnormalities and not on the organ in which... Read more »
The Trump administration’s plan for strengthening the nation’s cyber defenses is starting to come into focus.
Rob Joyce, a special assistant to the president and the White House’s cybersecurity coordinator, spoke in Boston Monday at an event promoting the launch of... Read more »
Celgene reported Monday that an experimental pill for the main type of multiple sclerosis met its main goals in a two-year study. By the end of the year, the Summit, NJ, drugmaker will ask the FDA to consider the drug, ozanimod,... Read more »
We are getting down to the wire—just two and a half weeks until Xconomy’s most unique, up close and personal event of the year: our sixth annual Napa Summit: The Xconomy Retreat on Technology, Jobs, and Growth. We have only about... Read more »
When Donald Trump heralded Ford’s announcement earlier this year that it would invest $1.2 billion in its Michigan plants, it was seen by some as the fulfillment of campaign promises to “bring jobs back” and put America first.
Last week, the... Read more »
Exhausted by the nonstop drama in Washington, DC? Immerse yourself instead in this week’s biotech headlines. Let’s start with a tribute to a life sciences icon, then we’ll head around the Xconomy network with early news from the nation’s big yearly... Read more »
Chris Garabedian, a veteran biotech executive who helped turn Sarepeta Therapeutics around before his controversial exit in 2015, has returned to the life sciences scene—this time with a new venture to form some biotech startups and help others find their footing.... Read more »
The Boundless boys are at it again. Ariel Diaz and Aaron White, who previously co-founded Boston education startup Boundless, have moved to New York City to pursue a new tech venture.
The new company is called Blissfully, and it recently... Read more »
Drug pricing. The opioid epidemic. Boardroom diversity. Immigration crackdowns. The state of cancer care now, and in the future. These things aren’t just topics of conversation in Boston biotech circles, but nationwide. Connecting those two with some lively, candid discussions was... Read more »
We’re only two weeks away from New York Biotech Seizes the Momentum, which will take place Wednesday, May 31, at Alexandria Center for Life Science. If you’re already planning on attending, there’s no need to wait any longer—our Super Saver special... Read more »
Cancer drugmaker G1 Therapeutics raised $105 million in an IPO last night, the latest development in a recent uptick of biotech offerings.
G1, of Research Triangle Park, NC, sold 7 million shares at $15 apiece. G1 had to sell more shares... Read more »
Cybersecurity company Proofpoint, which helped slow the sweeping global ransomware attack WannaCry after it emerged Friday, has now discovered a much more insidious, profitable, and potentially widespread cyberattack called Adylkuzz.
Adylkuzz doesn’t demand, as WannaCry does, that victims pay a ransom... Read more »